


PRF's 2023 Financial Profile*


Total Operational Revenue

\$2,912,559



Total Expenses

\$3,685,592



* Net Assets = \$43,773,477, mainly attributable to proceeds from the 2021 sale of the Priority Review Voucher (PRV) issued after the historic FDA approval of lonafarnib as a treatment for Progeria. PRF's 10-year average net assets prior to this historic payment = \$4.63 million.